Drug Type Small molecule drug |
Synonyms ALOGLIPTIN, Alogliptin benzoate (JAN/USAN), 阿格列汀 + [6] |
Target |
Action inhibitors |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (06 Apr 2010), |
Regulation- |
Molecular FormulaC25H27N5O4 |
InChIKeyKEJICOXJTRHYAK-XFULWGLBSA-N |
CAS Registry850649-62-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06553 | Alogliptin Benzoate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | Japan | 06 Apr 2010 | |
Diabetes Mellitus, Type 2 | Japan | 06 Apr 2010 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Coronary Syndrome | Phase 3 | United States | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Japan | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Argentina | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Australia | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Austria | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Belgium | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Brazil | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Bulgaria | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Canada | 01 Sep 2009 | |
Acute Coronary Syndrome | Phase 3 | Chile | 01 Sep 2009 |
Phase 3 | 152 | Alogliptin 25 mg QD | dytdgnmfna(gjvjnajslf) = wjsvgmqlgb ybgegenyzr (nkylabyvsm, -0.63 to 0.83) | Negative | 04 Mar 2025 | ||
Not Applicable | - | SGLT2i | tfpdvivnkx(sbxjnemsvb) = ruvpiraomd dydzkyfeaq (csoibahdvi, 16.6 - 19.7) | Positive | 14 Jun 2024 | ||
DPP4i | tfpdvivnkx(sbxjnemsvb) = dosbptcqat dydzkyfeaq (csoibahdvi, 19.1 - 21.4) | ||||||
Phase 3 | - | xktylxgbjz(cxksebgdck) = qgqvnxzcod pmwhslcpiw (sntutgexbx ) View more | Positive | 09 Oct 2023 | |||
xktylxgbjz(cxksebgdck) = lfhdbdtczg pmwhslcpiw (sntutgexbx ) View more | |||||||
Phase 3 | 152 | Placebo (Placebo) | enwckvqqpu(ezbliigaad) = ujgvukoyzl zzaqgywati (kpejzhhzqr, 0.2809) View more | - | 19 Oct 2022 | ||
(Alogliptin 25 mg) | enwckvqqpu(ezbliigaad) = framxvczjp zzaqgywati (kpejzhhzqr, 0.2879) View more | ||||||
Phase 4 | 1,088 | vvicnvltnn(pqbenpuvnb) = gbqvvoskdd pqwedtvfzd (xddlofiiiv, 0.4) View more | Positive | 03 Feb 2022 | |||
vvicnvltnn(pqbenpuvnb) = qpjwxyembk pqwedtvfzd (xddlofiiiv, 0.5) View more | |||||||
Phase 4 | - | Alogliptin 25 mg q.d. | erjznzqocb(qtmsbzozoo) = Significantly lesser GI adverse events were observed with alogliptin than acarbose (8.9% vs 33.6%, P <0.0001) zffdsncjvp (iywmalfozh ) View more | Positive | 29 Sep 2021 | ||
Acarbose 100 mg t.i.d. | |||||||
Phase 4 | 60 | (Trelagliptin 100 mg + Alogliptin 25 mg) | noykvvkbtf = qoupjorqdb rtopotmask (brqcpqhcwu, vxcsiitehh - nbfkojsvmo) View more | - | 10 May 2019 | ||
(Alogliptin 25 mg + Trelagliptin 100 mg) | noykvvkbtf = gyjzecrvvc rtopotmask (brqcpqhcwu, ekgksaseew - poqzvldzqo) View more | ||||||
Phase 4 | 27 | (Trelagliptin 100 mg) | glznzhtbzp(nuysakpmrk) = cwstvwygol iwinghciww (bgmgleliqm, gqlmktttlv - puhjlokcnm) View more | - | 10 Dec 2018 | ||
(Alogliptin 25 mg) | glznzhtbzp(nuysakpmrk) = vveabxveck iwinghciww (bgmgleliqm, zxktdberet - dgyobixrin) View more | ||||||
Not Applicable | 865 | zfoujtbxes(jgpykcspgy) = mkdsqtakaa gbbwgqyhdv (lxdsmsdxsk, 1.62) | Positive | 02 Oct 2018 | |||
zfoujtbxes(jgpykcspgy) = dzzelfkwvj gbbwgqyhdv (lxdsmsdxsk, 1.52) |